Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
Video Library
Search the Video Library
Video Language
Filter by Cancer Type:
Displaying Results 31 - 45 of 156
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.
Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses the reasons behind using adjuvant chemotherapy for early stage NSCLC patients. Clinical studies have shown that adding chemotherapy after surgery for lung cancer can indeed improve survival. Adjuvant Chemotherapy for Early Stage
All of us at the Global Resource for Advancing Cancer Education are very excited to introduce our newest project - the GRACE Spanish Lung Cancer Library. This collection of videos with our Spanish speaking faculty will discuss the basics of lung cancer for Spanish speaking patients and caregivers
¿Cuál es el tratamiento más apropiado para pacientes mayores con cáncer pulmonar de células no pequeñas avanzado? ¿La edad altera las recomendaciones?
For our 5th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the most appropriate treatment for elderly patients with advanced NSCLC, and whether age alters the recommendations.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.